Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of FluBHPVE6E7 Immunotherapy in Patients With HPV16- Associated Oropharyngeal Squamous Cell Carcinoma

NCT06589609 is registered in ClinicalTrials.gov with BlueSky Immunotherapies GmbH as lead sponsor.

NCT NCT06589609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06589609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of FluBHPVE6E7 Immunotherapy in Patients With HPV16- Associated Oropharyngeal Squamous Cell Carcinoma
Lead sponsor
BlueSky Immunotherapies GmbH
Phase
Phase 1
Overall status
Recruiting
Start date
August 23, 2024
Completion date
November 30, 2029
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oropharyngeal squamous cell carcinoma (scc)